About
Applied Pharmaceutical Science, Inc. (APS) is a leading company focus on frontier innovative drug research. APS aims to explore life science research, innovate precise cancer therapy, and to seek new hope for cancer patients around the world with breakthrough cancer therapies.
For many years, APS has focused on meeting clinical needs, focusing on the forefrontof global technology, and has been involved in the biopharmaceutical industry. Committed tobuilding an innovative new drug development platform that focuses on target and targetdependent discovery, tumor immune microenvironment, small molecule and small nucleic acidtechnology, and focuses on indications for cancer, tumor immunity, and liver diseases.
Applied Pharmaceutical Science, Inc. (APS) is a leading cancer precision therapy company. APS focuses on developing unmet genetic driver cancer therapies by deep understanding of cancer genetics, protein structure and function, synthetic medicinal chemistry, experiment and computation integrated verification technology, and has developed efficient de novo innovation ability based on advanced instruments for research and development. APS aims to revolutionize the treatment of disease and provide revolutionary targeted cancer therapies.
Unmet clinical needs oriented, APS Pharma is committed to building technology platforms on target and target dependency discovery, tumor immune microenvironment, small molecules, and siRNA, and developing innovative medicines for indications such as cancer, immuno-oncology, and liver diseases.
Management Team
Yuxun Wang, M.D., Ph.D.
Chief Executive Officer
Xiaohui Wang, MD.,Ph.D.
VP of Clinical Medicine
Jun Zhong, Ph.D.
VP of R&D
Zongbao Wang
VP of Clinical Operations
Chang Li
VP of Operations
Guocheng Liu，Ph.D.
VP of Nucleic Acid Medicinal Chemistry
ZizhongLi， Ph.D
VP of Medicinal Chemistry
Scientific Advisory Board
Alexander Drilon, MD
Memorial Sloan Kettering Cancer Center
Vivek Subbiah, MD
University of Texas MD Anderson Cancer Center
Company History
- 2011
- 2016
- 2021
- 2022
- 2023
- 2024
- 2026
- 2028
Company Establishment:
Applied Pharmaceutical Science, Inc. has been officially established.
New Positioning:
Applied Pharmaceutical Science, Inc. adheres to the mission of researching breakthrough therapies for tumors, seeking new hope for global cancer patients, building an international leading product pipeline, and creating a leading enterprise in the field of precise tumor treatment. Our company is positioned as a cancer precision treatment company with the mission of researching breakthrough therapies for tumors and seeking new hope for global cancer patients.
Complete FDA IND Application:
The second generation RET inhibitor APS03118 has completed the FDA IND application; in the same year, we rapidly expanded the clinical team compilation to provided rigorous, scientific, safe, and effective clinical trial data support for the product launch.
Base Construction:
Build a professional technical service platform and a new drug screening and evaluation process for the entire process of new drug research and development. The base is equipped with internationally advanced and specialized experimental conditions and a first-class domestic bioengineering technology team with international level. Independent research and development and project cooperation and introduction can achieve integrated landing and transformation.
First Clinical Patient Enrolled for APS03118 Project:
This marks the official start of clinical trials. Continuously promote the process of drug research and development.
Add new pipelines：
Small nucleic acid technology platform
The tumor dual immunosuppressive agent project has been fully launched.
IPO：
Deep integration of capital and biopharmaceutical technology to expand financing channels. Improving enterprise management and capital systems, making enterprise operations more standardized and transparent, attracting global talents, enhancing global market reputation, and accelerating enterprise development.
Becoming a leading enterprise:
Independent innovation and attracting the transformation of global leading biotechnology achievements, we will become a leading
international biopharmaceutical enterprise that tackles major human diseases and contributes to human health.
